Urology Devices Market Size, Minimally Invasive Treatment Trends and Growth Forecast 2026–2034

Urology Devices Market Overview Analysis By Fortune Business Insights

Market at a Glance

According to Fortune Business Insights: The global urology devices market was valued at USD 39.03 billion in 2025 and is projected to grow from USD 41.77 billion in 2026 to USD 75.48 billion by 2034, at a CAGR of 7.68% during the forecast period. North America led the market with a 37.11% share in 2025, valued at USD 14.49 billion.

Urology devices encompass a wide range of instruments and consumables used in the diagnosis and treatment of urological conditions including kidney stones, bladder cancer, prostate cancer, and chronic kidney disease. Key device categories include cystoscopes, ureteroscopes, laser and lithotripsy systems, dialysis equipment, and a broad range of accessories such as catheters, dilators, and sheaths.

Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/106686

Key Market Drivers

1. Rising Prevalence of Urological Disorders The growing global burden of chronic kidney disease, end-stage renal failure, bladder disorders, and urolithiasis is a primary force driving demand for urology devices. Projections indicate that the number of chronic kidney failure cases will exceed 6.0 million by 2030, sustaining a large and expanding patient pool requiring dialysis and minimally invasive surgical interventions.

2. Growing Adoption of Single-Use Cystoscopes Single-use flexible cystoscopes are transforming clinical practice by reducing infection risk, eliminating reprocessing time, and offering consistent diagnostic quality. Boston Scientific's January 2024 launch of the VeraVue Single-Use Flexible Cystoscope — designed to assist healthcare professionals in diagnosing and treating urinary tract conditions — is a notable example of this shift. Research data from Ambu USA indicates that single-use cystoscopes reduce total procedure time from approximately 18 minutes to just 10 minutes compared to reusable counterparts, a meaningful efficiency gain in high-volume clinical settings.

3. R&D and Technological Innovation Increasing investment in advanced urology devices is accelerating market growth. In February 2023, Ethicon announced the first robotic-assisted kidney stone removal using the Monarch platform, offering reduced retreatment rates and lower complication risks. The April 2023 launch of Mozarc Medical — a joint venture between Medtronic and DaVita focused on kidney health technology — further illustrates the strategic push toward patient-centered innovation in nephrology and urology.

4. Mergers, Acquisitions, and Portfolio Expansion Strategic consolidation continues to reshape the competitive landscape. Teleflex's 2023 acquisition of Palette Life Sciences strengthened its urological devices portfolio, while Boston Scientific's 2024 agreement to acquire Axonics expanded its offerings in urinary and bowel dysfunction treatment. These moves reflect a broader industry trend of building diversified, technology-led urology product lines.

Market Segmentation Highlights

By Product Type: The accessories segment dominates with a projected 58.53% share in 2026, driven by widespread adoption of catheters, dilators, and other consumables across clinical settings. The endoscopes segment is also expanding rapidly, fueled by demand for disposable cystoscopes that streamline scheduling and reduce cross-contamination risk.

By Application: Kidney diseases hold the largest application share at 43.20% in 2026, reflecting the high global prevalence of chronic kidney disease and end-stage renal disorders. The bladder disorders segment is growing significantly, with the American Cancer Society estimating 82,290 new bladder cancer cases in the U.S. alone by the end of 2023.

By End-User: Hospitals and ambulatory surgical centers lead with a 51.98% share in 2026, driven by increasing patient visits for urological diagnosis and the widespread use of cystoscopes and ureteroscopes. Dialysis centers represent the fastest-growing end-user segment, reflecting growing patient demand for kidney failure treatment and rising awareness of dialysis services worldwide.

Regional Insights

North America maintains market leadership, benefiting from robust healthcare infrastructure, high rates of technological adoption, and strong regulatory momentum — including FDA clearance of platforms such as Ethicon's Monarch robotic surgery system and KARL STORZ's Blue Light Cystoscopy system.

Europe holds a 28.28% market share, supported by CE-mark approvals for advanced devices like Ambu's HD single-use cystoscope and a large patient population affected by bladder and kidney disorders.

Asia Pacific is the fastest-growing region, driven by improving healthcare infrastructure in China, India, and Japan, growing disease awareness, and significant investment in medical device manufacturing. China and Japan alone are projected to contribute USD 3.2 billion and USD 2.14 billion respectively by 2026.

Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/106686

Restraining Factors

The market faces headwinds from complications associated with cystoscopy — including infection, bleeding, and bladder perforation — which have prompted increased FDA scrutiny of reprocessed urological endoscopes. Additionally, the high cost of urology devices, whether as upfront capital expenditures for reusable equipment or ongoing costs for disposables, remains a barrier to broader adoption, particularly in lower-income healthcare settings.

Competitive Landscape

Leading players include Fresenius Medical Care, Boston Scientific Corporation, Coloplast A/S, Becton Dickinson (BD), KARL STORZ, Olympus Corporation, Stryker, and Ambu A/S. Competitive strategies center on product innovation, strategic acquisitions, regulatory approvals, and geographic expansion into emerging markets — positioning the industry for sustained growth through 2034.